News Archive 2023
2023 News Archive - UCLA Institute of Urologic Oncology
December 8, 2023 - – Continued coverage of an interview with Dr. Andrew Goldstein, associate professor of molecular, cell and developmental biology and urology at the David Geffen School of Medicine, member of the UCLA Health Jonsson Comprehensive Cancer Center, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.
December 5, 2023 - Technology Networks – Coverage of a UCLA study led by Dr. Andrew Goldstein, associate professor of molecular, cell, and developmental biology and urology at the David Geffen School of Medicine.
Additional Coverage: , , , .
September 6, 2023 - .
Healthline provides coverage of study led by Dr. Amar Kishan, a member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA. Additional coverage: , and .
August 28, 2023 - . Dr. Amar Kishan, a member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, provided expert commentary to News-Medical.
August 25, 2023 - . Dr. Wayne Brisbane, assistant professor of urology at the David Geffen School of Medicine at UCLA provided expert commentary to the Urology Times.
August 9, 2023 - Urology Times . Continued coverage of new UCLA and UCSF study. Dr. Loïc Djaïleb, a visiting associate professor at the David Geffen School of Medicine at UCLA is the study's first author, with Dr. Jeremie Calais, an associate professor and director of the Clinical Research Program of the Ahmanson Translational Theranostics Division in the Department of Molecular and Medical Pharmacology at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center as co-senior author. Additional coverage: , Physician's Weekly Online Urology Times –Continued coverage of new UCLA and UCSF study. Dr. Loïc Djaïleb, a visiting associate professor at the David Geffen School of Medicine at UCLA is the study's first author, with Dr. Jeremie Calais, an associate professor and director of the Clinical Research Program of the Ahmanson Translational Theranostics Division in the Department of Molecular and Medical Pharmacology at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center as co-senior author. Additional coverage: , Physician's Weekly Online
July 25, 2023 - . A molecular imaging tool developed by researchers at the University of California's two nationally ranked medical centers, UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer recurrence in patients with intermediate to high-risk prostate cancer who undergo surgery. Dr. Jeremie Calais and Dr. Robert Reiter are authors.
July 25, 2023 - PSMA PET imaging improves accuracy of predicting prostate cancer recurrence. and covered the new UCLA and UCSF study. Dr. Loic Djaileb, a visiting associate professor at the David Geffen School of Medicine at UCLA is the study's first author, with Dr. Jeremie Calais, an associate professor and director of the Clinical Research Program of the Ahmanson Translational Theranostics Division in the Department of Molecular and Medical Pharmacology at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center as co-senior author.
July 12, 2023 - . Researchers from the UCLA Health Jonsson Comprehensive Cancer Center, including Dr. Christine Mona, Dr. Caius Radu, Dr. Johannes Czernin, have been awarded a $2 million grant from the National Cancer Institute to design better combination therapies that target the immune system to treat metastatic castration-resistant prostate cancer, which continues to spread even when testosterone levels are significantly reduced.
June 29, 2023 - Dr. Jeremie Calais, associate professor at the David Geffen School of Medicine at UCLA, director of the Ahmanson Translational Theranostics Division's clinical research program and member of the UCLA Health Jonsson Comprehensive Cancer Center's Cancer Molecular Imaging, Nanotechnology and Theranostics Program, provided expert commentary to about how new research shows viability of PET imaging agent for clear cell renal carcinoma.
June 27, 2023 - and provided coverage of a new study led by Dr. Leonard Marks, professor and deKernion Endowed Chair in Urology at the David Geffen School of Medicine at UCLA and member of UCLA Health Jonsson Comprehensive Cancer Center's Cancer Molecular Imaging, Nanotechnology and Theranostics Program, about how an AI model could help improve outcomes of prostate cancer focal therapy.
June 23, 2023 - Dr. Andrew Goldstein, associate professor of molecular, cell and developmental biology and urology at the David Geffen School of Medicine at UCLA, to study how metabolism changes in prostate cancer as a result of hormone therapy, the most commonly used treatment for men with advanced disease.
June 21, 2023 - interviewed Dr. Jeremie Calais, associate professor at the David Geffen School of Medicine at UCLA, director of the Ahmanson Translational Theranostics Division's clinical research program and member of the UCLA Health Jonsson Comprehensive Cancer Center's Cancer Molecular Imaging, Nanotechnology and Theranostics Program, about PSMA PET's influence on Prostate Cancer Studies. Dr. Calais was also interviewed for another story on .
June 6, 2023 - Dr. Paul Boutros, vice dean of research, professor in human genetics and urology at the David Geffen School of Medicine at UCLA. Provided expert commentary to regarding DNA sequencing for cancer patients.
June 2, 2023 - Dr. Isla P. Garraway, associate professor of urology at the David Geffen School of Medicine at UCLA, member of the UCLA Health Jonsson Comprehensive Cancer Center, and member of the Broad Center for Regenerative Medicine and Stem Cell Research at UCLA, discusses the unique aspects of prostate cancer research within the VA healthcare system on .
May 23, 2023
of highlighting UCLA physicians and scientists presenting at the American Society of Clinical Oncology's annual meeting, including a presentation by Dr. Brian Shuch, Associate Professor of Urology, Director of the Kidney Cancer Program, and Meinhardt Chair for Kidney Cancer Research, regarding the
May 8, 2023 - Dr. Brian Shuch, Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at UCLA, provided expert commentary to about how imaging with 89Zr-DFO-Girentuximab may better identify kidney tumors.
April 25, 2023 - Dr. Wayne Brisbane, assistant professor of urology at the David Geffen School of Medicine at UCLA, provided expert commentary to about Unfold AI, an artificial intelligence (AI)–powered software application program, being used for the management of patients with prostate cancer.
April 23, 2023 - about how researchers create a framework for evaluating how fast a cancer will grow. An international team of researchers led by UCLA's Dr. Paul Boutros, professor in the departments of human genetics and urology and interim vice dean for research at the David Geffen School of Medicine at UCLA and director of the UCLA Health Jonsson Comprehensive Cancer Center's Cancer Data Science program, have created a new way to accurately estimate how fast an individual cancer is evolving using open-source software, which makes big data sets easily accessible to the public. The findings can be used to develop more highly targeted cancer treatments. A paper detailing their method is in the journal of Nature Biotechnology.
April 3, 2023 - Nazy Zomorodian, NP, Director of the Genitourinary Clinical Trials Unit and Assistant Professor and Nurse Practitioner for the UCLA Urology, provided commentary to regarding the FDA's approval of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) as a combination therapy for patients with urothelial cancer.
April 3, 2023 - Dr. Amar Kishan, member of the IUO, UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, discusses GI toxicity reduction with MRI-Guided SBRT in prostate cancer with .
March 10, 2023 - Dr. Matthew B. Rettig, medical director of the Prostate Cancer Program at the Institute of Urologic Oncology at UCLA, appeared on to discuss the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer.
March 10, 2023 - Expert commentary from Dr. Jeremie Calais, assistant professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center and the Institute of Urologic Oncology at UCLA, was provided to about the role of PSMA-PET imaging in metastatic-castrate resistant prostate cancer.
February 23, 2023 - interviewed Dr. Amar Kishan, member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, about the optimal sequencing of ADT in nonmetastatic prostate cancer.
February 21, 2023 - Dr. Matthew Rettig, medical director of the Prostate Cancer Program at the Institute of Urologic Oncology at UCLA, provided expert commentary to about new options for metastatic prostate cancer.
February 3, 2023 - Dr. Amar Kishan, member of the UCLA IUO and UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, provided expert commentary to regarding World Cancer Day and practical advice for care.
February 2, 2023 - Dr. Amar Kishan, member of the UCLA IUO and UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, met with to discuss how MRI-guided SBRT could represent a safer, more precise radiotherapy option for prostate cancer.
January 30, 2023 - interviewed Dr. Amar Kishan, member of the UCLA IUO and UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, about the MIRAGE trial for prostate cancer.
January 18, 2023 - Continued coverage in of UCLA research led by Dr. Amar Kishan, member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA. Additional coverage: MedPage Today, eCancer, MIMS Urology
January 13, 2023 - reports that Dr. Isla P. Garraway, associate professor of urology at the David Geffen School of Medicine at UCLA, member of the UCLA Health Jonsson Comprehensive Cancer Center and member of the Broad Center for Regenerative Medicine and Stem Cell Research at UCLA, is a featured panelist on the Prostate Cancer Foundations's newly established health equities panel creating prostate cancer screening guidelines for Black men in the United States.
January 12, 2023 - reports on new UCLA research led by Dr. Amar Kishan, member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, that shows that MRI-guided radiotherapy improves treatment for localized prostate cancer.
January 10, 2023 - MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer according to new research, led by Dr. Amar Kishan, from the first randomized phase III clinical trial to directly compare MRI-guided stereotactic body radiotherapy (SBRT) with the same therapy guided by CT are and highlighted by the .
January 10, 2023 - provides expert commentary from Dr. Jeremie Calais, assistant professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the IUO, about PSMA PET imaging in clinical practice.
January 3, 2023 - provides expert commentary from Dr. Jeremie Calais, assistant professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the IUO, about PSMA PET imaging in clinical practice.
January 2, 2023 - provides expert commentary from Dr. Karim Chamie, associate professor of urology at the David Geffen School of Medicine at UCLA, about the interim findings from an ongoing study (NCT03022825) looking at the safety and efficacy of combining Nogapendekin alfa inbakicept (NAI) with BCG intravesical instillation for the treatment of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC).1